Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcγRIIIb on neutrophils

Leukemia Research

Volumn 34, Issue 5, 2010, Pages 666-671

  Nakagawa, Tomoaki ^a   Natsume, Akito ^a   Satoh, Mitsuo ^a   Niwa, Rinpei ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Antibody dependent cellular cytotoxicity; Apoptosis; Immunotherapy; Neutrophil; Nonfucosylated antibody; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIBODY; FC RECEPTOR IIA; FC RECEPTOR IIIB; KM 3065; LYMPHOCYTE ANTIGEN; RITUXIMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; CROSS LINKING; FLOW CYTOMETRY; FUCOSYLATION; HUMAN; HUMAN CELL; LYMPHOMA CELL; NEUTROPHIL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; HUMANS; LYMPHOMA; NEUTROPHILS; RECEPTORS, IGG;

EID: 77950074334     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.10.029     Document Type: Article

References (34)

1. Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C., et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949-954.
2. Kawaguchi Y., Kono K., Mimura K., Sugai H., Akaike H., Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007, 120:781-787.
3. Kimura H., Sakai K., Arao T., Shimoyama T., Tamura T., Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007, 98:1275-1280.
4. Kurai J., Chikumi H., Hashimoto K., Yamaguchi K., Yamasaki A., Sako T., et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007, 13:1552-1561.
5. Varchetta S., Gibelli N., Oliviero B., Nardini E., Gennari R., Gatti G., et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007, 67:11991-11999.
6. Cruz R.I., Hernandez-Ilizaliturri F.J., Olejniczak S., Deeb G., Knight J., Wallace P., et al. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leuk Lymphoma 2007, 48:2424-2436.
7. Golay J., Manganini M., Rambaldi A., Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 2004, 89:1476-1483.
8. Dall'Ozzo S., Tartas S., Paintaud G., Cartron G., Colombat P., Bardos P., et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004, 64:4664-4669.
9. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-3947.
10. Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006, 103:4005-4010.
11. Niwa R., Hatanaka S., Shoji-Hosaka E., Sakurada M., Kobayashi Y., Uehara A., et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 2004, 10:6248-6255.
12. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003, 278:3466-3473.
13. Natsume A., Niwa R., Satoh M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Design Devel Therapy 2009, 3:7-16.
14. Shan D., Ledbetter J.A., Press O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998, 91:1644-1652.
15. Li B., Shi S., Qian W., Zhao L., Zhang D., Hou S., et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res 2008, 68:2400-2408.
16. Zhang N., Khawli L.A., Hu P., Epstein A.L. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res 2005, 11:5971-5980.
17. Niwa R., Natsume A., Uehara A., Wakitani M., Iida S., Uchida K., et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2005, 306:151-160.
18. Shibata-Koyama M., Iida S., Misaka H., Mori K., Yano K., Shitara K., et al. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol 2009, 37:309-321.
19. Ravetch J.V., Perussia B. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med 1989, 170:481-497.
20. Ravetch J.V., Bolland S. IgG Fc receptors. Annu Rev Immunol 2001, 275-290.
21. Lichtenstein A.K., Ganz T., Selsted M.E., Lehrer R.I. Synergistic cytolysis mediated by hydrogen peroxide combined with peptide defensins. Cell Immunol 1988, 114:104-116.
22. Shibata-Koyama M., Iida S., Okazaki A., Mori K., Kitajima-Miyama K., Saitou S., et al. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation. Glycobiology 2009, 19:126-134.
23. Hofmeister J.K., Cooney D., Coggeshall K.M. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000, 26:133-143.
24. Shan D., Ledbetter J.A., Press O.W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000, 48:673-683.
25. van Sorge N.M., van der Pol W.L., van de Winkel J.G. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003, 61:189-202.
26. Fleit H.B., Wright S.D., Unkeless J.C. Human neutrophil Fc gamma receptor distribution and structure. Proc Natl Acad Sci USA 1982, 79:3275-3279.
27. Kuijpers T., Tool A., van der Schoot C., Ginsel L., Onderwater J., Roos D., et al. Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. Blood 1991, 78:1105-1111.
28. Valerius T., Repp R., de Wit T., Berthold S., Platzer E., Kalden J., et al. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 1993, 82:931-939.
29. Kushner B.H., Cheung N.K. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood 1992, 79:1484-1490.
30. Elsasser D., Valerius T., Repp R., Weiner G.J., Deo Y., Kalden J.R., et al. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 1996, 87:3803-3812.
31. Ottonello L., Morone P., Dapino P., Dallegri F. Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokinine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Blood 1996, 87:5171-5178.
32. Hernandez-Ilizaliturri F.J., Jupudy V., Ostberg J., Oflazoglu E., Huberman A., Repasky E., et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003, 9:5866-5873.
33. van der Kolk L.E., Grillo-Lopez A.J., Baars J.W., van Oers M.H. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia 2003, 17:1658-1664.
34. Gelderman K.A., Tomlinson S., Ross G.D., Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 2004, 25:158-164.